News Releases

Summary Toggle Teligent, Inc. Announces FDA Approval of Gentamicin Sulfate Ointment USP, 0.1%

BUENA, N.J. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

January 2, 2019

PDF Version
Summary Toggle Teligent, Inc. Executes $120 Million Financing Agreement

BUENA, N.J. , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), (“Teligent” or the “Company”) announced today that on December 13, 2018 the Company entered into a definitive first lien revolving credit agreement with ACF Finco I LP , a limited partnership affiliated with Ares

December 13, 2018

PDF Version
Summary Toggle Teligent, Inc. Receives Notification of Deficiency From NASDAQ Related to the Delayed Filing of Form 10-Q

BUENA, N.J. , Nov. 16, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), on November 13, 2018 received a standard notice from NASDAQ stating that, as a result of not having timely filed its quarterly report on Form 10-Q for the quarterly period ended September 30, 2018 , Teligent is not in

November 16, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces $120 Million Financing Commitment From Ares

BUENA, N.J. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), (“Teligent” or the “Company”) announced today that the Company secured a financing commitment from funds managed by Ares Management, L.P. (“Ares”) (NYSE: ARES), on November 12, 2018. Pursuant to the commitment, Ares

November 13, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces Third Quarter 2018 Results

BUENA, N.J. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (the "Company"), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2018 . Third Quarter 2018 Highlights Total revenue of $18.3

November 13, 2018

PDF Version
Summary Toggle Teligent, Inc. to Hold Conference Call for Third Quarter 2018 Results

BUENA, N.J. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Tuesday November 13 th , 2018 to discuss the 3 rd quarter 2018 financial results and business

November 12, 2018

PDF Version
Summary Toggle Teligent, Inc. to Present at Jefferies London Healthcare Conference on Wednesday November 14, 2018

BUENA, N.J. , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Jefferies London Healthcare Conference . The Conference is taking place November 14-15, 2018 in London, UK .

November 2, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Desoximetasone Ointment USP 0.05%

BUENA, N.J. , Oct. 24, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

October 24, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Fluocinonide Cream USP, 0.05%

BUENA, N.J. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

October 17, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Fluocinonide Ointment USP, 0.05%

BUENA, N.J., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of

October 2, 2018

PDF Version